Human Microbiome Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Human Microbiome Therapeutics Market is segmented By Technology (Shotgun, Targeted Gene, RNA, Whole Genome, and others), By Technique (Synthesis By Ligation, Pyro, Sanger, and others), By Application (Therapeutics, Genetic Screening, Drug Discovery, Biomarker Discovery, Personalized Medicines, and others), By End User (Research Institutes, Pharmaceutical, and Biotechnology Companies and others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Human Microbiome Therapeutics Market is expected to reach a CAGR of 29.8% during the forecast period (2024-2031). 

The human body serves as a host to a networked community of microbiome that outnumbers the body's cells. The microbiome comprises all of the genetic material within a microbiota that is equivalent to the entire collection of microorganisms in a specific niche, such as the human gut or oral cavity. The interaction between the human microbiome and the immune system affects several human metabolic functions and impacts well-being. The microbiome is a viable alternative for disease research, providing a more detailed analysis of the species present in the microbiome. The study of the human microbiome is done to determine the role of these microbes in human health and diseases caused as the microbes present may be pathogenic or beneficial.

Market Summary

For more details on this report - Request for Sample

Market Dynamics

The human microbiome market growth is driven by several factors, such as massive investment in microbiome research, an increase in government funding, and technological advancements.

The microbiome is attracting a lot of investment from the government as well as prominent private organizations. There are various companies and startups that are working in the field which accounts for a total of around 120. According to a report published by the Wall Street Journal, the investment in microbiome firms has increased from 2011 to 2015 by about 500%. The increase in investment and funding is due to the awareness of the uses and harms of the microbiome and how they affect the human body. Such discoveries can lead to breakthroughs in many human disease treatments. For instance, uBiome, a company working in the microbiome segment, is developing genomic tests meant to identify and diagnose harmful microbes in the body. One of the applications of the microbiome is personalized medicine, Human Longevity Inc., is putting $220 million into the microbiome DNA to uncover disease-associated imbalances in microbial populations. This latter case is aimed at the development of personalized medicines for patients with different conditions.

The government of developed economies is also aware of the importance of the microbiome and thus has initiated many million-dollar projects for the research and development of the field. For instance, the Human Microbiome Project (HMP) by the National Institute of Health set the goal of identifying and characterizing the microorganisms that are found in association with both healthy and diseased humans, and the National Microbiome Initiative, has accelerated research on the human microbiome are the two major products initiated by the U.S. government in the field of the human microbiome. The project was funded by $115 million by the U.S. government.

The Next Generation is getting technologically advanced to produce massive datasets in a short period. It has also reduced the cost of the microbiome. Similarly, bioinformatics tools used for metagenomic analysis, especially for translating raw sequences into meaningful data, are continually developing with the aim of providing the ability to examine both the taxonomic and the functional composition of diverse metagenomes. A number of the specialized software programs available for analyzing metagenomic data such as FastQC, Fastx-Toolkit, PRINSEQ, and many others that review that take into consideration user-friendliness, ease of access, open-source availability, ability to analyze metagenomic datasets, and ability to provide graphical representations of the analyzed data.

Market Segmentation Analysis

By technology, the global human microbiome market is segmented into the shotgun, targeted gene, RNA, whole genome, and others. Among these shotgun is expected to hold a dominant market share over the period of forecast (2019-2026) due to a faster process than other methods. Shotgun involves randomly breaking up DNA sequences into lots of small pieces and then reassembling the sequence by looking for regions of overlap. The shotgun is particularly efficient if there is an existing reference sequence. It is much easier to assemble the genome sequence by aligning it to an existing reference genome. The shotgun is much faster and less expensive than other methods that require a genetic map.

Based on technique the market is segmented into synthesis by, synthesis by ligation, pyro, sanger, and others. Out of these segments, synthesis is expected to dominate the global human microbiome market in the period of forecast (2019-2026).  synthesis is a widely adopted next-generation technology worldwide, responsible for generating more than 90% of the world's data.  by synthesis, technology supports both single-read and paired-end libraries. By synthesis, technology offers a short-insert paired-end capability for high-resolution genome, as well as long-insert paired-end reads for efficient sequence assembly.

Based on application the market is segmented into therapeutics, genetic screening, drug discovery, biomarker discovery, personalized medicines, and others. Among the following personalized medicines are expected to grow at the highest CAGR over the period of forecast (2019-2026). Personalized medicine is an approach for medical decisions, practices, and interventions that consider individual variations in genes, environment, and lifestyle for each person. Regarding intricate metabolic patterns associated with different diseases, characterizing the unique metabolic patterns of each patient is a practical approach. Microbiome analysis of individuals can help manufacture personalized medicines suitable to an individual's needs. Moreover, an improved understanding of the human microbiome could lead to the development of novel therapeutic strategies for different diseases. Potential therapeutic agents, such as personalized probiotic and prebiotic supplements, dietary interventions, and fecal microbiota transplantation that can be used to reshape the gut microbiome, are all forms of personalized medicine that can be done with the microbiome.

By end-users, the market is segmented into research institutes, pharmaceutical, and biotechnology companies, and others. Pharmaceutical and biotechnology companies are expected to hold a dominant position over the period of forecast (2019-2026) due to the rise in funding by the government and an increase in venture capitalism. Many new companies are rising in the field and are getting ample support from the respective governments.

Market Geographical Share

North America is dominating the human microbiome market in 2018 and is estimated to hold the largest market size over the forecast period (2019-2026), owing to the highly aware public, favorable government initiatives, higher adaptation of new technological advancements, and an increase in research and development. The US government supports genomics research through various government bodies, like the National Human Genome Research Institute, which supports the work on of the human genome, and funds research on the genome's structure, function, and role in health and disease.

Many companies present in the region are designing and developing many microbiome therapies. The application of the human microbiome is beneficial for various treatment areas such as cancer, inflammatory bowel disease, diabetes, autoimmune diseases, and more. Multiple programs for public awareness of probiotics and prebiotics are being organized in the U.S. For instance, in February 2018, the 3rd Annual North America Microbiome Congress was held in San Diego, by Kisaco Research that focused on five microbiome niches such as the gut, lung, oral, skin, and vaginal, and provided the latest insights on microbiome research, clinical trials, and collaborative partnerships.

Market Companies and Competitive Landscape

Some of the major key players in the market are BaseClear BV, Clinical Microbiomics AS, Locus Biosciences, Microbiome Insights Inc., Microbiome Therapeutics LLC, MR DNA, Second Genome, uBiome, Molzym GmbH, and Zymo Research Corp.

Key Developments

In the human microbiome market, the key players are adopting various growth strategies such as new product launches, partnerships, and collaborations with multiple research institutes and increasing research and development and high investment which are contributing to the growth of the human microbiome market globally.

1. In March 2019, BaseClear received the new ISO/IEC 17025 scope which now includes Next-Generation. The ISO/IEC 17025 accreditation is granted to laboratory tests that meet internationally validated quality requirements.
2. In January 2019, Locus Biosciences Enters a Collaboration and License Agreement with Johnson&Johnson to Develop CRISPR-Cas3 Bacteriophage Therapeutics
3. In January 2019, BaseClear significantly increased its capacity with the implementation of the Illumina NovaSeq 6000 platform. This new NGS platform has a tremendous data output of up to 3.000 Gb data per run.
4. In April 2018, Microbiome Therapeutics, LLC announced the launch of BiomeBliss®, a patented, first-in-class prebiotic dietary supplement specially developed to support a healthy gastrointestinal (GI) microbiome.